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Ureaplasma infections in pre-term infants: Recent 
information regarding the role of Ureaplasma species 
as neonatal pathogens
Although numerous clinical observational studies have been con  ducted 
over a period of over 30 years, the clinical significance of Ureaplasma 
infection is still under debate. The Ureaplasma speices. is a commensal 
in the female genital tract and considered to have of low virulence; 
however, Ureaplasma colonization has been associated with infertility, 
stillbirth, preterm delivery, histologic chorioamnionitis, and neonatal 
morbidities, including congenital pneumonia, meningitis, bronch-
opulmonary dysplasia, and perinatal death. Recently, Ureaplasma 
was subdivided into 2 separate species and 14 serovars. Ureaplasma 
parvum is known as biovar 1 and contains serovars 1, 3, 6, and 14, and 
Ureaplasma urealyticum (biovar 2) contains the remaining serovars (2, 4, 
5, and 7-13). The existence of differences in pathogenicities of these 14 
serovars and 2 biovars is controversial. Although macrolides are the only 
antimicrobial agents currently available for use in neonatal ureaplasmal 
infections, in the current clinical field, it is difficult to make decisions 
regarding which antibiotics should be used. Future investigations 
involving large, multicenter, randomized, controlled studies are needed 
before proper recommendations can be made for clinical practice.  
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ducted over a period of over 30 years, the clinical significance of 
these bacteria is still under debate
4). These bacteria are considered 
to be of low virulence; however, Ureaplasma colonization has 





9), and perinatal death in neonates
10).
This article summarizes recent information on the role of 
Ureaplasma infection in diseases in preterm infants and future 
considerations. 
Introduction
Ureaplasma species are the most common bacteria detected 
in urogenital infections, including nongonococcal urethritis in 
men and multiple obstetrical complications in women
1, 2). Since 
Ureaplasma spp. can be found in vaginal flora in 40% of sexually 
inactive and 67% sexually active women, it is known as a commensal 
in the female genital tract
3).  
Although numerous clinical observational studies were con-990      TJ Sung • Ureaplasma infections in preterm infants
Ureaplasma spp. 
1. Classification and characteristics 
Ureaplasma spp. is a member of the Mollicutes class, which is 
comprised of 4 orders, 5 families, 8 genes, and nearly 200 known 
species, 17 of which are known to use humans as their primary 
host
4). Another well-known member of the Mollicutes class is My-
co  plasma spp., in which there are 3 species, Mycoplasma hominis, 
Mycoplasma genitalium, and Mycoplasma fermentans, which are 
known to occur in the female urogenital tract. Ureaplas  ma was first 
described by Shepard in the 1950s and were detected in the male 
urethritis
11). Recently, Ureaplasma was subdivided into 2 separate 
species and 14 serovars that have been grouped according to 16S 
dRNA sequencing results into 2 genetically related biovars
3, 4).
U. parvum, known as biovar 1, contains serovars 1, 3, 6, and 
14, and U. urealyticum (biovar 2) contains the remaining serovars 
(2, 4, 5, and 7-13)
12). Characteristics of all serovars include lack of 
cell walls, limited biosynthetic abilities, small genome size, and 
mucosal association in the human host
3). The unique characteristic 
of Ureaplasma is their ability to hydrolyze urea to generate metabolic 
energy
1, 4). Some debates still occur regarding whether there is a 
difference in pathogenicity exists among these 14 serovars and 2 
biovars. 
2. Virulence factors
Ureaplasma can directly activate the first component of com-
plements and attach to host erythrocytes, neutrophils, spermatozoa, 
and urethral epithelial cells
1). This can induce inflammation in 
humans and produces multiple manifestations of clinical diseases
4). 
Since Ureaplasma spp. metabolizes urea to generate energy, it also 
produces secretory products such as ammonia, which may induce a 
local cytotoxic effect.  
Previously reported ureaplasmal virulence factors include IgA 
protease, urease, phospholipases A and C, and production of 
hydrogen peroxide
13). These factors may allow the organism to 
evade mucosal immune defenses by degrading IgA and injuring 
mucosal cells through the local generation of ammonia, membrane 
phospholipid degradation, prostaglandin synthesis, and membrane 
peroxidation
3). Although phenotypic production of IgA protease 
and phopholipases was described several years ago, genome 
examination of multiple serovars has failed to reveal genes encoding 
these enzymes
4).
The multiple-banded antigen (MBA) of Ureaplasma spp. is the 
predominant antigen recognized during the infection process and 
may be involved in host inflammatory response stimulation. It 
undergoes a high rate of variation in vitro and exhibits variable sizes 
in vitro on invasive isolates, suggesting that antigen size variation 
may be another mechanism through which the organism evades 
host defenses
3, 4). Ureaplasma serovars have multiple MBA genes, 
and some contain multiple copies of the same type of MBA gene.  
3. Vertical transmission and intrauterine infection 
Ureaplasmas can be isolated from endotracheal aspirations in up 
to 40% of newborn infants within 30 minutes to 24 hours after 
delivery
14, 15), and from maternal and umbilical cord blood at these 
delivery times
16). This provided evidence that vertical Ureaplasma 
transmission and neonatal infection may occur in newborn infants. 
Additionally, recovery of Ureaplasma from the chorion increased 
with the duration of membrane rupture, suggesting an ascending 
route of infection
17). Those born weighing less than 1,000 g are 
at higher risk of infection when the mother is colonized at up to 
90% of the infection rate
18). The possible pathogenesis involves fetal 
exposure to ascending ureaplasmal intrauterine infection, passage 
through an infected birth canal, hematogenous dissemination 
through the placenta into umbilical vessels, and colonization of the 
skin, mucosal membranes, respiratory tract, and dissemination into 
the blood and central nervous system
19, 20).  
Intrauterine infection is now believed to be a major cause of 
preterm birth, particularly in gestations of less than 30 weeks
21). 
Ureaplasma spp. is the most common isolate identified in amniotic 
fluid. Isolated Ureaplasma spp. from the chorioamnion has been 
consistently associated with histologic chorioamnionitis, which is 
inversely related to birth weight
22). Several experimental studies with 
intra-amniotic inoculation of U. parvum showed that it did not 
stimulate premature labor in mice
23) or sheep
24), but did stimulate 
progressive uterine contractions and preterm delivery in rhesus 
macaques
25). The Rhesus macaque experimental result suggests that 
species differences result in differences in host response or serovar 
differences in virulence. 
Ureaplasma spp. infection in neonatal pathogens
1. Congenital pneumonia in preterm infants
In the mid-1970s, some investigators suggested a potential role 
for Ureaplasma in neonatal respiratory disease after isolation of 
these organisms from lungs of stillborn infants with peumonitis
26). 
Evidence that Ureaplasma spp. cause congenital pneumonia 
includes isolation of bacteria in pure culture from amniotic fluid, 
affected lungs of neonates less than 14 hours after birth in the 
midst of an acute inflammatory response, and chorioamnion
1, 20). 
Other evidence includes demonstration of a specific IgM response 
in the neonate
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in culture-positive infants
28), demonstration of the bacteria in lung 
tissue using immunofluorescence
29), and electron microscopy
27). 
2. Bacteremia and systemic infections
Ureaplasma isolation from cord blood was first described in 
1969
30) and in a recent prospective study it was shown that 23% 
of infants had a positive cord blood culture for this organism
31). 
Cassell et al.
32) reported that 26% of neonates culture-positive for 
Ureaplasma spp. in the lower respiratory tract were bacteremia 
with these organisms. Ureaplasma has been isolated from gastric 
aspirates, blood, cerebrospinal fluid (CSF), lung, and brain tissue, 
although this organism is most commonly isolated from respiratory 
secretions
3). In 2 recent large prospective cohorts, Ureaplasma was 
detected in 17% of cord blood cultures and 23.6% of serum or CSF 
polymerase chain reaction (PCR) samples, with U. parvum as the 
predominant species detected in serum and CSF
10, 31).   
3. Meningitis and neonatal brain injury
The largest recent prospective survey of invasive infections 
analyzed samples from 313 very low-birth-weight (VLBW) infants 
with suspected sepsis/meningitis or hydrocephalus reported that the 
risk of severe intraventricular hemorrhage (IVH) (≥grade 3) was 2.5-
fold higher in serum PCR-positive than PCR-negative infants after 
adjustment for gestational age, but there was no association of cranial 
ultrasound abnormalities with detection of Ureaplasma in CSF
10).
A role for Ureaplasma in neonatal brain injury is supported by 
recent studies in experimental animal models
23). In the murine 
intrauterine U. parvum infection model, the brains of fetal and 
newborn mice showed evidence of microglial activation, deleted 
myelination, and disturbed neuronal development. Future 
studies are needed to provide additional information regarding 
mechanisms of Ureaplasma-mediated brain injury.  
4. Role of Ureaplasma infection in lung injury and inflam­
mation
Some investigators found that Ureaplasma isolated from lower 
respiratory tract colonization is associated with peripheral blood 
leukocytosis, particularly the neutrophil component
29, 33). Crouse 
et al.
28) evaluated chest radiographs of 44 preterm infants with 
Ureaplasma colonization the lower respiratory tract in comparison 
with those who were culture-negative. They found that pneumonia 
was twice as common in the Ureaplasma-positive group and early 
radiographic emphysematous changes within 2 weeks of birth were 
significantly more common in the Ureaplasma-positive group. 
In a recent cohort study of infants less than 33 weeks gestation, 
Ureaplasma spp. were detected during the first week of life in 
tracheal aspirates or nasopharyngeal aspirates in 35% of infants
10). 
These findings suggest an in utero onset of inflammatory responses 
and lung injury
3). 
Ureaplasma infection in neonate promotes a proinflammatory 
cytokine cascade in the lower respiratory tract; this infection is 
associated with an increase in tumor necrosis factors (TNF)-α , 
interleukin (IL)-1β , and IL-8
20) and blocks expression of the re-
gulatory cytokines IL-6 and/or IL-10
4). Viscardi et al.
33) examin  ed 
pathological specimens from Ureaplasma-infected infants and 
reported that Transforming growth factor (TGF)-β 1 expression 
increased in infants with pneumonia compared with control speci-
mens. Li and coworkers
34) demonstrated that human macrophages 
exposed to the Ureaplasma antigen produce TNF-α  and IL-6, 
and Ureaplasma-exposed macrophages release vascular endothelial 
growth factor and intracellular adhesion molecule-1.   
Animal models, such as mouse and primate models, have contri-
buted substantially to the understanding of how the inflammatory 
potential of ureaplasmal infection induces a deregulated, proinflam-
matory, interstitial pneumonitis leading to a profibrotic state
35, 36). 
5. Association of Ureaplasma infection with development 
of bronchopulmonary dysplasia 
The classic definition of bronchopulmonary dysplasia (BPD), a 
supplemental oxygen requirement at 28 days of age, has been criticized 
since widespread antenatal corticosteroid treatment, postnatal 
exogenous surfactant therapy, and gentler ventilator strategies in 
VLBW infants, a “new” BPD, emerged. Recently, Bancalari et 
al.
37) defined BPD as an oxygen requirement and the presence of 
radiographic abnormalities at 36 weeks postmenstrual age.   
Since BPD etiology is multifactorial and complex, the relation-
ship of Ureaplasma respiratory tract colonization with the develop-
ment of BPD has been debated. In 1988, 3 independent groups 
published results of cohort studies linking BPD development with 
airway colonization with Ureaplasma
18, 32, 38). A meta-analysis of 
17 clinical studies published before 1995 supported a significant 
association between Ureaplasma respiratory tract colonization 
and BPD development. Another recent meta-analysis conducted 
by Schelonka et al.
39), who analyzed 36 cohort studies published 
between 1988 and 2004 involving approximately 3000 preterm 
infants, showed a significant association between Ureaplasma 
respiratory colonization and BPD development whether it was 
defined as oxygen dependence at 28 days (P<0.001) or at 36 weeks 
postmenstrual age (P<0.001). Other studies support the Ureaplasma 
respiratory colonization-BPD association, particularly in the subset 
of Ureaplasma-colonized infants exposed to chorioamnionitis and 
leukocytosis at birth
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Castro-Alcaraz et al.
40) observed that persistent, but not transient, 
Ureaplasma respiratory complications are significantly higher in 
colonized infants. Mortality due to respiratory complications is 
significantly higher in colonized infants and the risk of a combined 
outcome measure of BPD or death due to lung disease was 4.2-
fold higher in colonized Ureaplasma rather than in noncolonized 
VLBW infants
14, 32).  
Infants with BPD have elevated proinflammatory cytokines such 
as IL-1, IL-6, and IL-8, with IL-8 acting as a potent neutrophil 
chemoattractant and, as a result, theses infants have elevated 
neutrophils in the lungs
20). Perinatal Ureaplasma infection may 
promote the inflammatory cascade in the lung and impair alveolar 
development directly or in conjunction with oxidant and ventilator-
induced lung injury
3, 20). Hence, postnatal application of high 
oxygen concentrations and mechanical ventilation and duration of 
exposure may potentiate the effect of Ureaplasma-associated injury 
to the lungs.     
Treatment of Ureaplasma infection in preterm infants
Although it is known that macrolides are the only antimicrobial 
agents currently available for use in the treatment of neonatal 
ureaplasmal infections, in the clinical field it is difficult to make 
decisions regarding which antibiotics should be used. Due to its 
toxicity, doxycycline is not an alternative unless U. urealyticum is 
isolated from CSF. Clindamycin has also been used to successfully 
treat systemic M. hominis infections in infants
1). As such, making 
specific recommendations for treating neonatal ureaplasma 
infections is difficult because the spectrum of ureaplasmal disease 
has not been fully described and there are very few clinical studies 
indicating the in vivo efficacy of antibiotics
1). Therefore, not only 
are choices between limited drug options controversial, but also the 
actual indications concerning conditions under which treatment 
should be offered, dosage, and duration of therapy is debated.   
Antibiotic therapy is a standard treatment modality for prema-
ture rupture of membranes (PROM). However, standard regimens 
failed to eradicate organisms including Ureaplasma or diminish 
inflammation in the amniotic cavity with PROM
41). In an experi-
mental Ureaplasma intraamniotic infection (IAI) in Rhesus 
monkeys, azitromycin alone or in combination with dexamethasone 
and indomethacin prevented fetal lung damage
42).
Despite the in vitro susceptibility of Ureaplasma to erythromycin, 
trials of erythromycin therapy in the first few weeks of life in 
Ureaplasma-colonized preterm infants have failed to demonstrate 
efficacy in preventing BPD
3). Recently, Walls and colleagues
43)
demonstrated that azithromycin prophylaxis, but not erythromycin, 
improved outcomes and reduced inflammation in a murine 
neonatal Ureaplasma infection model. This finding suggests 
that azithromycin is effective if administered immediately after 
birth. However, there have been no published investigations of 
azithromycin in neonates regarding low birth weight infants. 
Hence, until appropriate pharmacokinetics and efficacy trials are 
conducted, a dosing regimen for azithromycin in neonates cannot be 
recommended
41).  
Conclusions and future perspectives
Recent clinical and experimental studies have shown significant 
evidence that Ureaplasma infection may induce inflammatory 
processes early in utero and, as a result it can cause intrauterine 
chorioamnionitis, postnatal systemic infection, and lung injury, 
including BPD. However, more studies are needed to determine the 
relationship of Ureaplasma virulence factors, host immune factors 
affecting pathogen susceptibility, and inflammatory variability, and 
interactions with environmental factors such as oxygen exposure 
and mechanical ventilation
3). Furthermore, a study analyzing 
antimicrobial therapy of Ureaplasma-colonized infants should 
be conducted in a large, multicenter, randomized clinical trial to 
determine whether these antibiotics are effective in reducing BPD 
rate and improving neonatal outcomes.   
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